250 related articles for article (PubMed ID: 20718744)
1. Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice.
Feng Y; Huang SL; Dou W; Zhang S; Chen JH; Shen Y; Shen JH; Leng Y
Br J Pharmacol; 2010 Sep; 161(1):113-26. PubMed ID: 20718744
[TBL] [Abstract][Full Text] [Related]
2. Emodin, an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, regulates adipocyte function in vitro and exerts anti-diabetic effect in ob/ob mice.
Wang YJ; Huang SL; Feng Y; Ning MM; Leng Y
Acta Pharmacol Sin; 2012 Sep; 33(9):1195-203. PubMed ID: 22922341
[TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice.
Park SB; Jung WH; Kang NS; Park JS; Bae GH; Kim HY; Rhee SD; Kang SK; Ahn JH; Jeong HG; Kim KY
Eur J Pharmacol; 2013 Dec; 721(1-3):70-9. PubMed ID: 24135201
[TBL] [Abstract][Full Text] [Related]
4. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
Park JS; Rhee SD; Jung WH; Kang NS; Kim HY; Kang SK; Ahn JH; Kim KY
Eur J Pharmacol; 2012 Sep; 691(1-3):19-27. PubMed ID: 22760069
[TBL] [Abstract][Full Text] [Related]
5. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, UI-1499.
Byun SY; Shin YJ; Nam KY; Hong SP; Ahn SK
Life Sci; 2015 Jan; 120():1-7. PubMed ID: 25447448
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 11β-HSD1 by LG13 improves glucose metabolism in type 2 diabetic mice.
Zhao L; Pan Y; Peng K; Wang Z; Li J; Li D; Tong C; Wang Y; Liang G
J Mol Endocrinol; 2015 Oct; 55(2):119-31. PubMed ID: 26220348
[TBL] [Abstract][Full Text] [Related]
7. HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Okazaki S; Takahashi T; Iwamura T; Nakaki J; Sekiya Y; Yagi M; Kumagai H; Sato M; Sakami S; Nitta A; Kawai K; Kainoh M
J Pharmacol Exp Ther; 2014 Oct; 351(1):181-9. PubMed ID: 25100752
[TBL] [Abstract][Full Text] [Related]
8. The 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against the insulin resistance and hepatic steatosis in db/db mice.
Yuan X; Li H; Bai H; Zhao X; Zhang C; Liu H; Zhang Y; Zhao B; Wu Y; Liu J; Xiang Q; Feng B; Chu Y; Huang Y
Eur J Pharmacol; 2016 Oct; 788():140-151. PubMed ID: 27242185
[TBL] [Abstract][Full Text] [Related]
9. Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.
Masuzaki H; Flier JS
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):255-62. PubMed ID: 14683456
[TBL] [Abstract][Full Text] [Related]
10. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
Hong SP; Han D; Chang KH; Ahn SK
Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
[TBL] [Abstract][Full Text] [Related]
11. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
12. Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice.
Liu Y; Nakagawa Y; Wang Y; Liu L; Du H; Wang W; Ren X; Lutfy K; Friedman TC
J Mol Endocrinol; 2008 Aug; 41(2):53-64. PubMed ID: 18524870
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
Akiyama N; Akiyama Y; Kato H; Kuroda T; Ono T; Imagawa K; Asakura K; Shinosaki T; Murayama T; Hanasaki K
J Pharmacol Exp Ther; 2014 Apr; 349(1):66-74. PubMed ID: 24511146
[TBL] [Abstract][Full Text] [Related]
14. Curcumin as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats.
Hu GX; Lin H; Lian QQ; Zhou SH; Guo J; Zhou HY; Chu Y; Ge RS
PLoS One; 2013; 8(3):e49976. PubMed ID: 23533564
[TBL] [Abstract][Full Text] [Related]
15. BVT.2733, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, attenuates obesity and inflammation in diet-induced obese mice.
Wang L; Liu J; Zhang A; Cheng P; Zhang X; Lv S; Wu L; Yu J; Di W; Zha J; Kong X; Qi H; Zhong Y; Ding G
PLoS One; 2012; 7(7):e40056. PubMed ID: 22768329
[TBL] [Abstract][Full Text] [Related]
16. A potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, SKI2852, ameliorates metabolic syndrome in diabetic mice models.
Oh H; Jeong KH; Han HY; Son HJ; Kim SS; Lee HJ; Kim S; Sa JH; Jun HS; Ryu JH; Choi CS
Eur J Pharmacol; 2015 Dec; 768():139-48. PubMed ID: 26519792
[TBL] [Abstract][Full Text] [Related]
17. Addressing the role of 11β-hydroxysteroid dehydrogenase type 1 in the development of polycystic ovary syndrome and the putative therapeutic effects of its selective inhibition in a preclinical model.
Li X; Hu S; Zhu Q; Yao G; Yao J; Li J; Wang Y; Ding Y; Qi J; Xu R; Zhao H; Zhu Z; Du Y; Sun K; Sun Y
Metabolism; 2021 Jun; 119():154749. PubMed ID: 33722534
[TBL] [Abstract][Full Text] [Related]
18. Antisense reduction of 11β-hydroxysteroid dehydrogenase type 1 enhances energy expenditure and insulin sensitivity independent of food intake in C57BL/6J mice on a Western-type diet.
Li G; Hernandez-Ono A; Crooke RM; Graham MJ; Ginsberg HN
Metabolism; 2012 Jun; 61(6):823-35. PubMed ID: 22209663
[TBL] [Abstract][Full Text] [Related]
19. 11β-Hydroxysteroid dehydrogenase type 1 shRNA ameliorates glucocorticoid-induced insulin resistance and lipolysis in mouse abdominal adipose tissue.
Wang Y; Yan C; Liu L; Wang W; Du H; Fan W; Lutfy K; Jiang M; Friedman TC; Liu Y
Am J Physiol Endocrinol Metab; 2015 Jan; 308(1):E84-95. PubMed ID: 25389364
[TBL] [Abstract][Full Text] [Related]
20. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms.
Harno E; Cottrell EC; Yu A; DeSchoolmeester J; Gutierrez PM; Denn M; Swales JG; Goldberg FW; Bohlooly-Y M; Andersén H; Wild MJ; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Dec; 154(12):4580-93. PubMed ID: 24169553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
